Tesamorelin: Targeted Approach to Visceral Fat

Visceral fat—the fat stored around abdominal organs—poses greater metabolic risks than subcutaneous fat. Tesamorelin is a GHRH analog that has shown specific activity against visceral adipose tissue. ## Why Visceral Fat Matters Visceral adipose tissue (VAT) is metabolically active and associated with: - Insulin resistance - Inflammatory cytokine production - Cardiovascular risk - Metabolic syndrome Unlike subcutaneous fat, visceral fat can be harder to target through diet and exercise alone. ## Tesamorelin's Mechanism Tesamorelin stimulates endogenous GH release through GHRH receptors. The resulting increase in growth hormone drives lipolysis, with a preferential effect on visceral fat: - GH increases fat breakdown - Effect is pronounced in visceral tissue - Subcutaneous fat is relatively spared - No significant impact on muscle mass ## Clinical Evidence Tesamorelin is one of the few peptides with substantial human clinical data. Studies have demonstrated measurable reductions in trunk fat in various populations. ## Considerations Tesamorelin requires consistent daily injection. Results develop over weeks to months. It's often used as part of a broader approach to metabolic health optimization.